BeiGene, Ltd. (BGNE) Reaches $134.80 After 3.00% Up Move; Srs Investment Management Has Raised Its Salesforce Com (CRM) Holding

February 15, 2018 - By Hazel Jackson

The stock of BeiGene, Ltd. (NASDAQ:BGNE) is a huge mover today! The stock increased 4.30% or $5.56 during the last trading session, reaching $134.8. About 88,614 shares traded. BeiGene, Ltd. (NASDAQ:BGNE) has risen 36.36% since February 15, 2017 and is uptrending. It has outperformed by 19.66% the S&P500.The move comes after 8 months positive chart setup for the $7.17B company. It was reported on Feb, 15 by We have $138.84 PT which if reached, will make NASDAQ:BGNE worth $215.16 million more.

Srs Investment Management Llc increased Salesforce Com Inc (CRM) stake by 1.35% reported in 2017Q3 SEC filing. Srs Investment Management Llc acquired 31,500 shares as Salesforce Com Inc (CRM)’s stock rose 7.28%. The Srs Investment Management Llc holds 2.37 million shares with $221.29M value, up from 2.34 million last quarter. Salesforce Com Inc now has $81.12 billion valuation. The stock increased 3.01% or $3.29 during the last trading session, reaching $112.31. About 3.94M shares traded., inc. (NYSE:CRM) has risen 7.78% since February 15, 2017 and is uptrending. It has underperformed by 8.92% the S&P500.

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops molecularly-targeted and immuno-oncology drugs for the treatment of cancer. The company has market cap of $7.17 billion. The companyÂ’s clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations. It currently has negative earnings. The Company’s preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications.

Analysts await BeiGene, Ltd. (NASDAQ:BGNE) to report earnings on March, 28. They expect $-1.74 earnings per share, down 65.71% or $0.69 from last year’s $-1.05 per share. After $2.54 actual earnings per share reported by BeiGene, Ltd. for the previous quarter, Wall Street now forecasts -168.50% negative EPS growth.

Since August 15, 2017, it had 1 buy, and 100 insider sales for $74.37 million activity. $549,948 worth of, inc. (NYSE:CRM) was sold by Benioff Marc on Tuesday, January 16. Shares for $56,856 were sold by Allanson Joe on Tuesday, August 29. Another trade for 8,026 shares valued at $774,008 was made by Harris Parker on Tuesday, October 17. 10,000 shares were sold by BLOCK KEITH, worth $980,981. Roos John Victor also sold $14,616 worth of, inc. (NYSE:CRM) on Thursday, February 1. Martinez Maria had sold 940 shares worth $87,185. Another trade for 111,646 shares valued at $10.62M was sold by Hawkins Mark J.

Among 51 analysts covering (NYSE:CRM), 45 have Buy rating, 1 Sell and 5 Hold. Therefore 88% are positive. had 199 analyst reports since August 21, 2015 according to SRatingsIntel. Robert W. Baird maintained, inc. (NYSE:CRM) rating on Tuesday, October 31. Robert W. Baird has “Buy” rating and $110.0 target. The rating was maintained by Canaccord Genuity on Thursday, May 19 with “Buy”. The stock of, inc. (NYSE:CRM) earned “Underperform” rating by Bernstein on Thursday, November 19. The rating was maintained by Northland Capital on Friday, October 27 with “Buy”. The firm has “Buy” rating by Roth Capital given on Thursday, November 19. The rating was downgraded by OTR Global on Monday, August 15 to “Mixed”. The rating was maintained by RBC Capital Markets on Sunday, July 30 with “Buy”. The stock of, inc. (NYSE:CRM) earned “Buy” rating by Wells Fargo on Wednesday, November 22. The rating was upgraded by Wedbush on Friday, December 18 to “Outperform”. As per Thursday, September 1, the company rating was maintained by Barclays Capital.

Investors sentiment decreased to 1.34 in 2017 Q3. Its down 0.04, from 1.38 in 2017Q2. It is negative, as 40 investors sold CRM shares while 234 reduced holdings. 73 funds opened positions while 295 raised stakes. 609.74 million shares or 0.30% less from 611.55 million shares in 2017Q2 were reported. Cornerstone has 3,993 shares for 0.26% of their portfolio. Hbk Sorce Advisory invested 0.05% in, inc. (NYSE:CRM). Adirondack Trust Co has invested 0.02% in, inc. (NYSE:CRM). Private Advisor Group Ltd Liability Corp reported 14,247 shares or 0.03% of all its holdings. Moreover, Arrowgrass Capital Partners (Us) Limited Partnership has 0.04% invested in, inc. (NYSE:CRM). Tradewinds Capital Management Ltd Co reported 15 shares. Baystate Wealth stated it has 0% in, inc. (NYSE:CRM). Lazard Asset Limited reported 350 shares. Glaxis Capital Mngmt Ltd holds 9.06% or 63,670 shares. R G Niederhoffer Mngmt Inc has 2.1% invested in, inc. (NYSE:CRM). Peddock Capital Advisors Ltd has invested 0.07% in, inc. (NYSE:CRM). Welch And Forbes Limited Liability Com holds 0.01% or 2,642 shares in its portfolio. Fred Alger Mgmt reported 3.61 million shares or 1.58% of all its holdings. 15,000 are held by Ally Fin Inc. New York State Common Retirement Fund has 0.25% invested in, inc. (NYSE:CRM).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts